Independent Analyst Comment: Pfizer and AstraZeneca Deal
With regard to Pfizer’s potential takeover of AstraZeneca, Ali Al-Bazergan, analyst at Datamonitor Healthcare said:
"There are a numerous motivations behind Pfizer courting — primarily, it would add AstraZeneca’s much coveted early-stage drugs in immuno-oncology, with many provided breakthrough status and development pushed into Phase III. It also allows Pfizer to explore an outlet for repatriating its cash-pile overseas, tap into potential tax, capital and operational synergies, and lastly grooms an infrastructure to extract even more value in potential streamlining divestments.
"The deal sparks debate about the UK’s capability to remain an influential player in the life sciences industry, primarily whether it can continue to maintain competitiveness, draw investment, and attract the best talent. AstraZeneca’s strength lies in its research on immuno-oncology yet the deal will inevitably see R&D synergies explored [in mind of Pfizer’s UK closures], threatening AstraZeneca’s research operations, and plans to open its new site in Cambridge."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.